Celldex a new overweight at Morgan Stanley on urticaria candidate
Source: SeekingAlpha
2025-03-20 11:44:08 ET
More on Celldex
- Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?
- Seeking Alpha’s Quant Rating on Celldex
- Historical earnings data for Celldex
- Financial information for Celldex
Read the full article on Seeking Alpha
For further details see:
Celldex a new overweight at Morgan Stanley on urticaria candidate
Celldex Therapeutics Inc.
NASDAQ: CLDX
CLDX Trading
3.14% G/L:
$31.40 Last:
523,139 Volume:
$30.87 Open:
CLDX Latest News
February 27, 2026 02:45:00 pm
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA
February 25, 2026 04:01:00 pm
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
CLDX Stock Data
$1,661,236,775
63,525,694
0.16%
57
N/A
Biotechnology & Life Sciences
Healthcare
US
Hampton
